Open Access

Inhibitory effect of gefitinib derivative LPY‑9 on human glioma

  • Authors:
    • Yuchen Sun
    • Liangzhao Chu
    • Huijuan Wang
    • Han Peng
    • Jian Liu
  • View Affiliations

  • Published online on: June 30, 2021     https://doi.org/10.3892/mmr.2021.12262
  • Article Number: 623
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the effects of a gefitinib derivative, LPY‑9, on the proliferation, apoptosis and migration of human glioma cell line U251‑MG by CCK8, Transwell or flow cytometry, and the effect of LPY‑9 on the activity of caspase‑3 enzyme and related proteins in the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways by western blot and ELISA. It was found that LPY‑9 exhibited higher a inhibitory effect on the proliferation of U251‑MG cell lines compared with gefitinib and it also exhibited a certain dose‑dependence. Following LPY‑9 treatment, typical apoptotic morphology was observed under the microscope after Giemsa staining. LPY‑9 induced apoptosis at low concentration, and the activity of caspase‑3 enzyme increased with the increase in drug concentration, significantly inhibiting the secretion of VEGF in a dose‑dependent manner. The effect was notably more evident compared with gefitinib at the same concentration. The expression level of caspase‑3 and cleaved caspase‑3 increased with the increase in LPY‑9 concentration; however, expression levels of VEGF, EGFR, phosphorylated AKT and PI3K decreased with the increase of LPY‑9 concentration and no change was observed in the expression level of AKT. LPY‑9 inhibited the proliferation of the human glioma cell line U251‑MG, promoted apoptosis and effectively inhibited the migration of U251‑MG cells. The effect of LPY‑9 was more noticeable compared with gefitinib. The results of the present study may provide a foundation for further study and clinical research of this as an anti‑tumor drug in animal models.
View Figures
View References

Related Articles

Journal Cover

September-2021
Volume 24 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun Y, Chu L, Wang H, Peng H and Liu J: Inhibitory effect of gefitinib derivative LPY‑9 on human glioma. Mol Med Rep 24: 623, 2021
APA
Sun, Y., Chu, L., Wang, H., Peng, H., & Liu, J. (2021). Inhibitory effect of gefitinib derivative LPY‑9 on human glioma. Molecular Medicine Reports, 24, 623. https://doi.org/10.3892/mmr.2021.12262
MLA
Sun, Y., Chu, L., Wang, H., Peng, H., Liu, J."Inhibitory effect of gefitinib derivative LPY‑9 on human glioma". Molecular Medicine Reports 24.3 (2021): 623.
Chicago
Sun, Y., Chu, L., Wang, H., Peng, H., Liu, J."Inhibitory effect of gefitinib derivative LPY‑9 on human glioma". Molecular Medicine Reports 24, no. 3 (2021): 623. https://doi.org/10.3892/mmr.2021.12262